Phase 2 N=187 Phase IIB TL + YCWP + DC in Melanoma
Melanoma
Primary: Disease Free Survival Assessment — 32; 30; 31; 30 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
Metastatic Prostate Carcinoma · Prostate Carcinoma Metastatic in the Bone · Stage IV Prostate Cancer
Primary: Mean Standardized Uptake Value (SUVmean) by Lesion Type — 1.91; 2.36; 2.63; 3.05 SUV by body weight (kg)
Phase 2 N=52 LY3214996 +/- HCQ in Pancreatic Cancer
Pancreatic Cancer · Advanced Cancer
Primary: Disease Control Rate (DCR) — 0; 1; 1; 1 Participants
Phase 2 N=20 Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
Heart Failure With Preserved Ejection Fraction
Primary: Maximal Exercise Capacity (Peak VO2) Assessed by Cardiopulmonary Exercise Testing — 1.0; 1.0 L/min
Phase 2 N=102 Ibudilast for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder
Primary: Percent Heavy Drinking Days — 67.4777; 65.65447; 53.88376; 42.96028 percent of heavy drinking days
Phase 2 N=41 A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
Chronic Graft-versus-host-disease
Primary: Phase 1: Number of Participants With DLTs — 0; 0; 0; 2 Participants
Phase 2 N=4 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Colon Adenocarcinoma · High-Frequency Microsatellite Instability · Metastatic Malignant Solid Neoplasm
Primary: Percentage of Circulating DNA Clearance — 0 percentage of DNA cleared
Phase 2 N=39 Transgender Estradiol Affirming Therapy
Transgenderism
Primary: Total Testosterone Level in Transgender Female Patients — 498.6; 481.3; 505.3; 62.7 pg/mL — p=0.005
Phase 2 N=39 A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
Inflammatory Bowel Diseases · Colitis, Ulcerative
Primary: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score — -6.4 score on a scale
Phase 2 N=44 Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
Locally Advanced Epithelioid Hemangioendothelioma · Metastatic Epithelioid Hemangioendothelioma · Unresectable Epithelioid Hemangioendothelioma
Primary: Objective Response Rate — 9.5 Percentage
Phase 2 N=30 Phase 2 Study of ONC201 in Neuroendocrine Tumors
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Phase 2 N=16 Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).
Pulmonary Hypertension
Primary: Calculated Pulmonary Vascular Resistance (PVR) — 7.97; 8.23; 7.27; 7.11 Wood units (WU) — p=0.541
Phase 2 N=79 Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome
Post COVID-19 Syndrome
Primary: Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Extreme Fatigue (ANCOVA Model) — -2.376; -2.430 score on a scale (10 points total) — p=0.9416
Phase 2 N=63 A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection · COVID-19 · Long COVID
Primary: Daily Diary Pain NRS — -2.2; -2.0 units on a scale
Phase 2 N=201 Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining (tCFS) at Day 60 — -2.04; -1.65; -2.15; -1.54 tCFS score on a scale of 0 - 20